Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress Genetics Investing
Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial Genetics Investing
Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results Genetics Investing
Sanofi: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Bioverativ Pharmaceutical Investing
Helix BioPharma Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities Genetics Investing
Primary Endpoint Successfully Achieved in Mesoblast’s Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease Genetics Investing
G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights Genetics Investing
Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares Genetics Investing
Photocure Announces U.S. FDA Approval of New Indications for Blue Light Cystoscopy Pharmaceutical Investing